<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00051090</url>
  </required_header>
  <id_info>
    <org_study_id>A5167</org_study_id>
    <secondary_id>10962</secondary_id>
    <secondary_id>ACTG A5167</secondary_id>
    <nct_id>NCT00051090</nct_id>
  </id_info>
  <brief_title>Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV</brief_title>
  <official_title>Multicenter, Pilot Study of Telbivudine (LdT) Anti-HBV Treatment Prior to the Initiation of Highly Active Antiretroviral Therapy Containing Lamivudine in Subjects Coinfected With HBV and HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      This study will evaluate the drug telbivudine (LdT) for treatment of hepatitis B virus (HBV)&#xD;
      in HIV infected patients. Patients will take telbivudine alone for 24 weeks, add anti-HIV&#xD;
      drugs for 24 weeks, then stop taking telbivudine while continuing their anti-HIV drug&#xD;
      regimen. To enroll in this study, patients must not be taking any anti-HIV drugs and cannot&#xD;
      have taken more than 31 days of treatment with lamivudine (3TC), protease inhibitors (PIs),&#xD;
      or nonnucleoside reverse transcriptase inhibitors (NNRTIs).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies indicate that 70% to 80% of HIV infected patients have or have had HBV infection and&#xD;
      that 10% are HBV carriers. Lamivudine therapy for treatment of HBV in HIV infected patients&#xD;
      has limited long-term efficacy due to the development of resistance mutations. Telbivudine is&#xD;
      a thymidine analogue with excellent HBV inhibitory activity but no anti-HIV activity. The&#xD;
      primary objective of this study is to evaluate the safety and anti-HBV activity of&#xD;
      telbivudine alone and in combination with a lamivudine-based highly active antiretroviral&#xD;
      therapy (HAART) regimen in patients coinfected with HBV and HIV.&#xD;
&#xD;
      Patients in this study will take telbivudine for 24 weeks. At Week 24, patients will add a&#xD;
      HAART regimen containing lamivudine and efavirenz plus either didanosine or abacavir.&#xD;
      Patients who are unable to add a HAART regimen at Week 24 due to lab abnormalities or other&#xD;
      contraindications will be allowed to delay the initiation of HAART until Week 30. Patients&#xD;
      may initiate HAART prior to Week 24 if deemed medically necessary by the primary HIV care&#xD;
      provider. Patients will take both telbivudine and HAART for 24 weeks. At Week 48, patients&#xD;
      will discontinue telbivudine and continue on the HAART regimen alone for an additional 12&#xD;
      weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HBV viral loads</measure>
    <time_frame>At Study entry, Week 24 and Week 48</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of telbivudine</measure>
    <time_frame>Throughout study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of HAART</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ALT level</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV genetic mutation status at HBV virologic failure</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV viral load</measure>
    <time_frame>At Study entry, Weeks 24, 48, and 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV viral load and hepatic transaminase concentrations</measure>
    <time_frame>At Week 60</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>HIV Infections</condition>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All eligible study participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telbivudine</intervention_name>
    <description>Administered orally at a daily dosage of 600 mg for a period of 48 weeks</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>Administered orally at a total daily dosage of 300 mg for Weeks 24-48</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <description>Administered orally at a daily dose of 600 mg</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Didanosine</intervention_name>
    <description>Administered orally at a total dosage of either 400 mg or 250 mg determined by individual weight</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abacavir</intervention_name>
    <description>Administered orally twice daily in doses of 300 mg</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV positive&#xD;
&#xD;
          -  No antiretroviral therapy within 6 months prior to study entry&#xD;
&#xD;
          -  Less than 31 days cumulative therapy with lamivudine, a protease inhibitor, or a&#xD;
             nonnucleoside reverse transcriptase inhibitor&#xD;
&#xD;
          -  Willingness to delay HAART until at least Week 24 of study&#xD;
&#xD;
          -  Ability to procure and initiate HAART regimen&#xD;
&#xD;
          -  CD4+ cell count &gt;= 250 cells/mm3 within 60 days prior to study entry&#xD;
&#xD;
          -  HIV-1 RNA &gt; 400 copies/ml within 60 days prior to study entry&#xD;
&#xD;
          -  Serum HBV DNA &gt;= 1,000,000 copies/ml within 60 days prior to study entry&#xD;
&#xD;
          -  Positive serum hepatitis B surface antigen (HbsAG)&#xD;
&#xD;
          -  Acceptable methods of contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Allergy, sensitivity, or intolerance to study drugs&#xD;
&#xD;
          -  Alcohol consumption averaging more than 1 drink/day within past 30 days&#xD;
&#xD;
          -  Decompensated cirrhosis&#xD;
&#xD;
          -  HCV antibody positive or known HCV RNA positive&#xD;
&#xD;
          -  HDV antibody positive&#xD;
&#xD;
          -  Certain medical conditions&#xD;
&#xD;
          -  Use of certain medications with anti-HBV activity within 90 days of study entry&#xD;
&#xD;
          -  Use of systemic corticosteroids within 30 days of study entry&#xD;
&#xD;
          -  Use of any systemic antineoplastic, immunomodulatory treatment, or radiation within 24&#xD;
             weeks of study entry&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Lynch, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://aidsinfo.nih.gov/clinicaltrials/htmltrials_sp.asp?an=1475</url>
    <description>Haga clic aquí para ver información sobre este ensayo clínico en español.</description>
  </link>
  <reference>
    <citation>den Brinker M, Wit FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, van Leeuwen R, Pakker NG, Reiss P, Danner SA, Weverling GJ, Lange JM. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 2000 Dec 22;14(18):2895-902.</citation>
    <PMID>11153671</PMID>
  </reference>
  <reference>
    <citation>Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000 Jan 5;283(1):74-80.</citation>
    <PMID>10632283</PMID>
  </reference>
  <reference>
    <citation>Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 2002 Jan;35(1):182-9.</citation>
    <PMID>11786975</PMID>
  </reference>
  <reference>
    <citation>Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, Opolon P, Katlama C, Poynard T. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology. 1999 Nov;30(5):1302-6.</citation>
    <PMID>10534354</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 3, 2003</study_first_submitted>
  <study_first_submitted_qc>January 3, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2003</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B</keyword>
  <keyword>Antiretroviral Therapy, Highly-Active</keyword>
  <keyword>HIV Infections</keyword>
  <keyword>Lamivudine</keyword>
  <keyword>Reverse Transcriptase Inhibitors</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Didanosine</mesh_term>
    <mesh_term>Telbivudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

